A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

AL Amyloidosis

Interventions

DRUG: CAEL-101
OTHER: Placebo
DRUG: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen

Sponsor

Alexion Pharmaceuticals, Inc.